KIT and gastrointestinal stromal tumor: Despite the impressive response rates (mainly observed for first-line targeted therapy), the efficacy of RTKis in GIST eventually declines, indicating the complexity of resistance mechanisms beyond the KIT/PDGFRA mutational state.